83435-58-9

Basic information

• Product Name: Boc-D-prolinol
• Synonyms: BOC-D-PRO-OL;BOC-D-PROLINOL;BOC-(R)-2-(HYDROXYMETHYL) PYRROLIDINE;N-TERT-BUTOXYCARBONYL-D-PROLINOL;N-T-BUTOXYCARBONYL-D-PROLINOL;N-T-BOC-D-PROLINOL;N-BOC-D-PROLINOL;N-ALPHA-T-BOC-D-PROLINOL
• CAS NO: 83435-58-9
• Molecular Formula: C₁₀H₁₉NO₃
• Molecular Weight: 201.26
• EINECS: 1592732-453-0
• Product Categories: Alcohol Aldehyde & acid series;Amino Acids;Chiral Building Blocks;Glycidyl Compounds, etc. (Chiral);Synthetic Organic Chemistry;Chiral Products
• Mol File: 83435-58-9.mol
• Article Data: 51

Chemical Properties

• Melting Point: 60-64 °C(lit.)
• Boiling Point: 289.5 °C at 760 mmHg
• Flash Point: 128.9 °C
• Appearance: White to light beige/Crystalline Powder
• Density: 1.084 g/cm₃
• Refractive Index: 54 ° (C=5, MeOH)
• Storage Temp.: Store at 0°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 14.77±0.10(Predicted)
• Water Solubility: insoluble
• CAS DataBase Reference: Boc-D-prolinol(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-D-prolinol(83435-58-9)
• EPA Substance Registry System: Boc-D-prolinol(83435-58-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-20/21/22
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 83435-58-9(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

N-(tert-Butoxycarbonyl)-D-prolinol is used to prepare (azetidinyl)methoxy]pyridines and 2-(aryloxymethyl) azacyclic analogs with therapeutic potetials for the treatment of central nervous system (CNS) disorders.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1315053-73-6 C₅H₁₁NO 
• 43041-12-9 methyl (2R)-pyrrolidine-2-carboxylate 
• 101555-60-6 2-(R)-carboxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 68832-13-3 D-prolinol 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 37784-17-1 N-(tert-butoxycarbonyl)-D-proline 
• 147-85-3 L-proline 
• 344-25-2 D-Prolin 
• 1301760-11-1 C₁₅H₂₅NO₅ 
• 15761-39-4 N-tert-butoxycarbonyl-proline 
• 145681-01-2 (+/-)-N-tert-butoxycarbonylproline methyl ester 
• 73323-65-6 1-(tert-butyl) 2-methyl (R)-pyrrolidine-1,2-dicarboxylate 

Downstream Products

• 1039826-29-3 (R)-tert-butyl 2-(bromomethyl)pyrrolidine-1-carboxylate 
• 1190890-12-0 tert-butyl (2R)-2-(aminomethyl)pyrrolidine-1-carboxylate hydrochloride 
• 1201580-77-9 6-{(R)-2-[(E)-2-(3-chlorophenyl)vinyl]pyrrolidin-1-yl}-9H-purine 
• 1201581-83-0 tert-butyl (R)-2-[(3-fluorophenylamino)methyl]pyrrolidine-1-carboxylate 
• 1201581-84-1 tert-butyl (R)-2-{[(3-fluorophenyl)methylamino]methyl}pyrrolidine-1-carboxylate 
• 1201581-85-2 tert-butyl (R)-2-[(E)-2-(3-chlorophenyl)vinyl]pyrrolidine-1-carboxylate 
• 1201581-98-7 (R)-2-[(E)-2-(3-chlorophenyl)vinyl]pyrrolidine 
• 1201581-96-5 (3-fluorophenyl)-(R)-1-pyrrolidin-2-ylmethylamine 
• 1201580-73-5 (3-fluorophenyl)-[(R)-1-(9H-purin-6-yl)pyrrolidin-2-ylmethyl]amine 
• 1201581-97-6 C₁₂H₁₇FN₂ 
• 1201580-75-7 (3-fluorophenyl)methyl-[(R)-1-(9H-purin-6-yl)pyrrolidin-2-ylmethyl]amine 
• 1384974-49-5 D-tert-butyl 2-[(4-(4,5-dihydro-4,4,5,5-tetramethyl-3-oxido-1H-imidazol-3-ium-1-oxyl-2-yl)-2-methoxyphenoxy)methyl]pyrrolidine-1-carboxylate 
• 1384974-51-9 D-tert-butyl 2-[(4-(4,5-dihydro-4,4,5,5-tetramethyl-3-oxido-1H-imidazol-3-ium-1-oxyl-2-yl)benzoyloxy)methyl]pyrrolidine-1-carboxylate 
• 1384974-47-3 D-tert-butyl 2-[(4-(4,5-dihydro-4,4,5,5-tetramethyl-3-oxido-1H-imidazol-3-ium-1-oxyl-2-yl)phenoxy)methyl]pyrrolidine-1-carboxylate 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Compound, preparation method thereof, pharmaceutical composition and application of compound

The invention discloses a compound, a preparation method thereof, a pharmaceutical composition and application of the compound. The compound I, and a stereoisomer or a pharmacologically acceptable salt thereof can serve as a CDK7 kinase inhibitor, are high in inhibition activity, and can be used for treatment of various malignant tumors.

FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.